Łukasz Magrowski

Łukasz Magrowski

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Łukasz Magrowski has a total of 40 co-authors. Here are the top co-authors by number of shared publications:

  • Marcin Miszczyk

    Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria

    2 shared publications
  • Oliwia Masri

    IIIrd Radiotherapy and Chemotherapy Department, Maria Skłodowska-Curie National Research Institute of Oncology, Wybrzeże Armii Krajowej 15, 44-102 Gliwice, Poland

    2 shared publications
  • Agnieszka Namysł-Kaletka

    Radiotherapy Department, Maria Skłodowska-Curie National Research Institute of Oncology, Wybrzeże Armii Krajowej 15, 44-102 Gliwice, Poland

    1 shared publication
  • Aleksandra Napieralska

    Department of Radiotherapy, Maria Sklodowska-Curie National Research Institute of Oncology, Branch Gliwice, Gliwice

    1 shared publication
  • Barbara Czapla

    IIIrd Radiotherapy and Chemotherapy Department, Maria Skłodowska-Curie National Research Institute of Oncology, Wybrzeże Armii Krajowej 15, 44-102 Gliwice, Poland

    1 shared publication
  • Benjamin Pradere

    Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria

    1 shared publication

Latest Publications

  • Open Access

    Brachytherapy boost improves survival and decreases risk of developing distant metastases compared to external beam radiotherapy alone in intermediate and high risk group prostate cancer patients

    by Marcin Miszczyk, Łukasz Magrowski, Tomasz Krzysztofiak, Rafał Stando, Wojciech Majewski, Konrad Stawiski, Oliwia Masri, Jakub Ciepał, Gabriela Depowska, Krystyna Chimiak, et al.


  • Open Access

    The Prognostic Value of PI-RADS Score in CyberKnife Ultra-Hypofractionated Radiotherapy for Localized Prostate Cancer

    by Marcin Miszczyk, Justyna Rembak-Szynkiewicz, Łukasz Magrowski, Konrad Stawiski, Agnieszka Namysł-Kaletka, Aleksandra Napieralska, Małgorzata Kraszkiewicz, Grzegorz Woźniak, Małgorzata Stąpór-Fudzińska, Grzegorz Głowacki, et al.

    Prostate Imaging-Reporting and Data System (PI-RADS) has been widely implemented as a diagnostic tool for significant prostate cancer (PCa); less is known about its prognostic value, especially in the setting of primary radiotherapy. We aimed to analyze the association between PI-RADS v. 2.1 classification and risk of metastases, based on a group of 152 patients treated with ultra-hypofractionated stereotactic CyberKnife radiotherapy for localized low or intermediate risk-group prostate cancer. We found that all distant failures (n = 5) occurred in patients diagnosed with a PI-RADS score of 5, and axial measurements of the target lesion were associated with the risk of developing metastases (p < 0.001). The best risk stratification model (based on a combination of greatest dimension, the product of multiplication of PI-RADS target lesion axial measurements, and age) achieved a c-index of 0.903 (bootstrap-validated bias-corrected 95% CI: 0.848–0.901). This creates a hypothesis that PI-RADS 5 and the size of the target lesion are important prognostic factors in early-stage PCa patients and should be considered as an adverse prognostic measure for patients undergoing early treatment such as radiation or focal therapy.


  • Open Access

    Effect of Ileal Transposition (IT) on Angiopoietin-Like Protein-8 (ANGPTL8) and Pentraxin (PTX3) Plasma Level in Sprague-Dawley Rats Fed High-Fat Diet (HFD)

    by Tomasz Sawczyn, Dominika Stygar, Katarzyna Nabrdalik, Michał Kukla, Oliwia Masri, Łukasz Magrowski, Wojciech Karcz, Jerzy Jochem

    Background. Metabolic surgery procedures are designed not only for sustained weight loss but also for achieving positive metabolic changes, including improved glucose tolerance and insulin sensitivity, along with an increase in energy expenditure. Based on recent findings, the present study focuses on the relationship between the effects of ileal transposition (IT), high-fat diet (HFD), and selected markers of lipid metabolism and inflammation. Methods. Forty-eight male rats were divided into two groups: HFD and control diet (CD) fed rats. After eight weeks, animals in each group were randomly assigned to two types of surgery: IT and SHAM. Thereafter, fifty percent of the animals in the HFD and CD groups had their diets changed, while the remaining half maintained their presurgery diets. Eight weeks after surgery, plasma levels of ANGPTL8, PTX3, leptin, and adiponectin were assessed. Results. The IT group pre- and postoperatively maintained on the HFD showed higher ANGPTL8 level compared to SHAM operated animals ( ). The effect of IT on PTX3 level in the group pre- and postoperatively maintained on a CD was not significant, and there were no differences compared to SHAM. Only the postoperative diet change to HFD increased PTX3 level in the IT operated animals ( ). The IT group had increased plasma adiponectin ( ) and leptin ( ) levels after dietary change to HFD compared to IT rats fed CD. Conclusions. This study indicates that the outcomes of metabolic surgery can be greatly modified by HFD. The effects of the IT procedure in this experiment are ambiguous and do not provide a clear answer as to whether or not they are beneficial.